Inogen, Inc (INGN) EVP Sells $1,168,100.00 in Stock
Inogen, Inc (NASDAQ:INGN) EVP Byron Myers sold 10,000 shares of the company’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $116.81, for a total transaction of $1,168,100.00. Following the completion of the transaction, the executive vice president now owns 48,600 shares in the company, valued at $5,676,966. The sale was disclosed in a filing with the SEC, which is available through this link.
Byron Myers also recently made the following trade(s):
- On Friday, November 17th, Byron Myers sold 35,000 shares of Inogen stock. The stock was sold at an average price of $116.77, for a total transaction of $4,086,950.00.
Inogen, Inc (INGN) opened at $119.49 on Friday. Inogen, Inc has a one year low of $62.69 and a one year high of $130.05. The stock has a market cap of $2,529.91, a P/E ratio of 98.55, a PEG ratio of 5.09 and a beta of 1.13.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same period last year, the firm earned $0.25 earnings per share. The company’s quarterly revenue was up 26.8% on a year-over-year basis. equities analysts expect that Inogen, Inc will post 1.19 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Piedmont Investment Advisors LLC bought a new position in shares of Inogen during the second quarter valued at approximately $336,000. Parametric Portfolio Associates LLC boosted its stake in shares of Inogen by 63.6% during the second quarter. Parametric Portfolio Associates LLC now owns 45,969 shares of the medical technology company’s stock valued at $4,386,000 after purchasing an additional 17,867 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Inogen by 24.9% during the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after purchasing an additional 301,737 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Inogen by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 293,070 shares of the medical technology company’s stock valued at $27,964,000 after purchasing an additional 13,160 shares in the last quarter. Finally, Koch Industries Inc. boosted its stake in shares of Inogen by 19,485.8% during the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares in the last quarter.
INGN has been the topic of a number of research analyst reports. Leerink Swann restated an “outperform” rating and issued a $120.00 target price (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 target price on shares of Inogen in a research note on Tuesday, September 12th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research note on Thursday, November 9th. Needham & Company LLC restated a “buy” rating and issued a $108.00 target price on shares of Inogen in a research note on Friday, September 1st. Finally, BidaskClub downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, December 5th. Four equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $103.14.
COPYRIGHT VIOLATION WARNING: “Inogen, Inc (INGN) EVP Sells $1,168,100.00 in Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/inogen-inc-ingn-evp-sells-1168100-00-in-stock/1765121.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with Analyst Ratings Network's FREE daily email newsletter.